Purpose： Stanniocalcin（STC） has been recognized as a potential biomarker in a variety of cancers. The aim of this study was to examine STC1 and STC2 expression in tumor and serum samples from gastric cancer（GC） p...Purpose： Stanniocalcin（STC） has been recognized as a potential biomarker in a variety of cancers. The aim of this study was to examine STC1 and STC2 expression in tumor and serum samples from gastric cancer（GC） patients.Methods： A total of 83 GC patients treated with radical resection were enrolled in this study. Immunohistochemistry was used to detect STC protein expression in paired tumor and adjacent normal tissues. Serum STC levels were determined by enzyme-linked immunosorbent assay（ELISA）. The receiver operating characteristics（ROC） curve was constructed to describe diagnostic specificity and sensitivity. Results： Both of STC1 and STC2 protein expression were upregulated in GC tissues compared with that in normal ones. Moreover, the high/moderate of STC1 protein was significantly associated with lymph metastasis, clinical stage and adverse 3-year progression-free survival（PFS）. In addition, serum STC1 and STC2 expression in GC patients were much higher than that in patients with benign gastric disease, which decreased at postoperative 7-10 days. The sensitivity of serum STC protein also showed superiority over CEA and CA19-9. Conclusions： STC upregulation plays an important role in GC development, and serum STC1 and STC2 might function as promising tumor markers for GC diagnosis and prognosis.展开更多
Advanced gastric cancer （GC） has been recognized as lethal disease when peritoneal metastases （PM） occurred.There is no standard treatment for advanced GC with PM.Until 1980s,the therapeutic arena for these patien...Advanced gastric cancer （GC） has been recognized as lethal disease when peritoneal metastases （PM） occurred.There is no standard treatment for advanced GC with PM.Until 1980s,the therapeutic arena for these patients had remained stagnant,with no therapeutic approach having shown a survival gain in GC with PM.However,cytoreductive surgery （CRS） with peritonectomy procedures and intraperitoneal chemotherapy （IPC） promising new combined therapeutic approach to achieve disease control for GC with PM.The recent publications changed the GC with PM treatment landscape by providing an evidence that CRS and IPC led to prolongation in overall survival （OS）.This review will provide an overview of the evolving role of CRS and IPC in the management of advanced GC with PM in the current era.展开更多
Postoperative adjuvant chemotherapy(ACT)confers superior gastric cancer(GC)survival in the Eastern cohort.However,is the current standard of ACT already excessive,or is it still necessary to increase its intensity for...Postoperative adjuvant chemotherapy(ACT)confers superior gastric cancer(GC)survival in the Eastern cohort.However,is the current standard of ACT already excessive,or is it still necessary to increase its intensity for specific subgroups?Tailored ACT strategies for GC depend on gradual exploration by clinical trials in selected patients.Thus,understanding the implications of previous and current research can help us respond wisely and design effective,rational trials,save medical resources and make better decisions in clinical practice.After reviewing and analyzing studies on ACT for GC patients undergoing curative resection,we found that research strategies for conducting"addition""ACT for specific stages of the disease have achieved great progress in making ACT more tailored and personalized in consideration of pathology stages.Furthermore,trials indicate that"addition"ACT strategies for GC patient subgroups based on histological characteristics might be helpful to move toward a more specific tailored and personalized management approach.Designing ACT research focused on different node statuses should also be conducted according to the biological specificity of lymph node(LN)metastasis.Therefore,future trials designed to determine tailored treatment based on histological and biological characteristics for specific subgroups are urgently needed and conducted as the theme of the 2019 American Society of Clinical Oncology(ASCO):Caring for Every Patient,Learning from Every Patient.展开更多
Objective： MicroRNAs （miRNAs） are important regulators that play a key role in tumorigenesis and rumor progression. Transforming growth factor-β1 （TGF-β1） is involved in invasion and metastasis in many tumors. ...Objective： MicroRNAs （miRNAs） are important regulators that play a key role in tumorigenesis and rumor progression. Transforming growth factor-β1 （TGF-β1） is involved in invasion and metastasis in many tumors. In this study, we investigated the microRNAs （miRNA） profiles altered by TGF-β1 in gastric cancer （GC） cells. Methods： We detected the expression profiles of miRNA by miRNA microarray and quantitative real- time polymerase chain reaction. Migration and invasion, wound-healing assay, prediction of miRNA targets, Western blot and qRT-PCR analysis were carried out to determine the role of one selected miRNA, namely miR-193b, in affecting the biological behaviors of GC BGC823 cells. Results： Among 847 human miRNAs in the microarray, three miRNAs （miR-27a, miR-29b-1 and miR-194） were up-regulated and three （miR-574-3p, miR-193b and miR-130b） were down-regulated in BGC823 cells treated with TGF-β1 compared with control, miR-193b suppressed the invasion and metastasis of GC cells in vivo and in vitro, and down-regulated urokinase-type plasminogen activator （uPA） protein in GC cells. Conclusions： TGF-β1 altered miRNA expression profile in BGC823 cells. Among the altered miRNAs, TGF-β1 induced the down-regulation of miR-193b, which inhibited cell invasion and metastasis in vivo and in vitro, and down-regulated uPA protein in GC cells.展开更多
目的:分析程序性细胞死亡受体-1(programmed cell death protein 1,PD-1)单抗联合曲妥珠单抗标准治疗在一线HER-2阳性晚期胃癌的临床疗效及安全性。方法:选取2019年6月至2021年6月河南省肿瘤医院HER-2阳性晚期胃癌患者110例,根据治疗方...目的:分析程序性细胞死亡受体-1(programmed cell death protein 1,PD-1)单抗联合曲妥珠单抗标准治疗在一线HER-2阳性晚期胃癌的临床疗效及安全性。方法:选取2019年6月至2021年6月河南省肿瘤医院HER-2阳性晚期胃癌患者110例,根据治疗方法分为研究组(48例)和对照组(62例),比较两组患者临床疗效及安全性。结果:中位随访时间14.2个月,研究组和对照组客观缓解率(overall response rate,ORR)分别为41.7%和37.1%,疾病控制率(disease controlrate,DCR)分别为87.5%和80.6%,中位无进展生存期(median progression-free survival,mPFS)分别为9.2个月和6.8个月(HR=0.624,95%CI:0.396~0.981;P=0.046)。两组患者免疫组织化学(immunohistochemistry,IHC)3+的mPFS分别为11.6个月和6.8个月(HR=0.461,95%CI:0.260~0.817;P=0.012),其中研究组IHC3+和IHC2+(in situ hybridization positive,ISH阳性)的mPFS分别为11.6个月和7.8个月(HR=0.486,95%CI:0.215~1.097;P=0.051),研究组中程序性细胞死亡配体1(programmed cell death-ligand 1,PD-L1)阳性和PD-L1阴性的mPFS分别为9.2个月和4.9个月(HR=0.370,95%CI:0.104~1.322;P=0.033)。研究组和对照组所有不良反应事件中,甲状腺功能减退(P=0.034)及中性粒细胞减少(P=0.046)差异具有统计学意义。多因素分析显示,ECOG评分、腹膜转移及治疗方案是PFS独立影响因素(均P<0.05)。结论:免疫联合曲妥珠单抗标准方案治疗HER-2阳性晚期胃癌具有良好临床疗效,可延长患者PFS,IHC3+患者免疫联合治疗效果可能更佳,且安全性可控。展开更多
基金supported by Natural Science Foundation of Jiangsu Province, China (No. BK2012371)
文摘Purpose： Stanniocalcin（STC） has been recognized as a potential biomarker in a variety of cancers. The aim of this study was to examine STC1 and STC2 expression in tumor and serum samples from gastric cancer（GC） patients.Methods： A total of 83 GC patients treated with radical resection were enrolled in this study. Immunohistochemistry was used to detect STC protein expression in paired tumor and adjacent normal tissues. Serum STC levels were determined by enzyme-linked immunosorbent assay（ELISA）. The receiver operating characteristics（ROC） curve was constructed to describe diagnostic specificity and sensitivity. Results： Both of STC1 and STC2 protein expression were upregulated in GC tissues compared with that in normal ones. Moreover, the high/moderate of STC1 protein was significantly associated with lymph metastasis, clinical stage and adverse 3-year progression-free survival（PFS）. In addition, serum STC1 and STC2 expression in GC patients were much higher than that in patients with benign gastric disease, which decreased at postoperative 7-10 days. The sensitivity of serum STC protein also showed superiority over CEA and CA19-9. Conclusions： STC upregulation plays an important role in GC development, and serum STC1 and STC2 might function as promising tumor markers for GC diagnosis and prognosis.
文摘Advanced gastric cancer （GC） has been recognized as lethal disease when peritoneal metastases （PM） occurred.There is no standard treatment for advanced GC with PM.Until 1980s,the therapeutic arena for these patients had remained stagnant,with no therapeutic approach having shown a survival gain in GC with PM.However,cytoreductive surgery （CRS） with peritonectomy procedures and intraperitoneal chemotherapy （IPC） promising new combined therapeutic approach to achieve disease control for GC with PM.The recent publications changed the GC with PM treatment landscape by providing an evidence that CRS and IPC led to prolongation in overall survival （OS）.This review will provide an overview of the evolving role of CRS and IPC in the management of advanced GC with PM in the current era.
基金supported by the National Natural Science Foundation of China (No. 81872013)National Key Research and Development Program (No.2017YFC 0108300)+1 种基金National Key Clinical Specialty Discipline Construction Program of China (No. [2012]121)Science and Technology Planning Project of Guangdong Province (No.2017B020226005)
文摘Postoperative adjuvant chemotherapy(ACT)confers superior gastric cancer(GC)survival in the Eastern cohort.However,is the current standard of ACT already excessive,or is it still necessary to increase its intensity for specific subgroups?Tailored ACT strategies for GC depend on gradual exploration by clinical trials in selected patients.Thus,understanding the implications of previous and current research can help us respond wisely and design effective,rational trials,save medical resources and make better decisions in clinical practice.After reviewing and analyzing studies on ACT for GC patients undergoing curative resection,we found that research strategies for conducting"addition""ACT for specific stages of the disease have achieved great progress in making ACT more tailored and personalized in consideration of pathology stages.Furthermore,trials indicate that"addition"ACT strategies for GC patient subgroups based on histological characteristics might be helpful to move toward a more specific tailored and personalized management approach.Designing ACT research focused on different node statuses should also be conducted according to the biological specificity of lymph node(LN)metastasis.Therefore,future trials designed to determine tailored treatment based on histological and biological characteristics for specific subgroups are urgently needed and conducted as the theme of the 2019 American Society of Clinical Oncology(ASCO):Caring for Every Patient,Learning from Every Patient.
基金supported by Natural Science Foundation of China(No.81001080)Natural Science Foundation of China(No.30901452)
文摘Objective： MicroRNAs （miRNAs） are important regulators that play a key role in tumorigenesis and rumor progression. Transforming growth factor-β1 （TGF-β1） is involved in invasion and metastasis in many tumors. In this study, we investigated the microRNAs （miRNA） profiles altered by TGF-β1 in gastric cancer （GC） cells. Methods： We detected the expression profiles of miRNA by miRNA microarray and quantitative real- time polymerase chain reaction. Migration and invasion, wound-healing assay, prediction of miRNA targets, Western blot and qRT-PCR analysis were carried out to determine the role of one selected miRNA, namely miR-193b, in affecting the biological behaviors of GC BGC823 cells. Results： Among 847 human miRNAs in the microarray, three miRNAs （miR-27a, miR-29b-1 and miR-194） were up-regulated and three （miR-574-3p, miR-193b and miR-130b） were down-regulated in BGC823 cells treated with TGF-β1 compared with control, miR-193b suppressed the invasion and metastasis of GC cells in vivo and in vitro, and down-regulated urokinase-type plasminogen activator （uPA） protein in GC cells. Conclusions： TGF-β1 altered miRNA expression profile in BGC823 cells. Among the altered miRNAs, TGF-β1 induced the down-regulation of miR-193b, which inhibited cell invasion and metastasis in vivo and in vitro, and down-regulated uPA protein in GC cells.
